ROCK2-IN-7 

ROCK2-IN-7 is a kinase inhibitor targeting to ROCK2. ROCK2-IN-7 inhibits ROCK2/pSTAT3 Signaling. ROCK2-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model^[1].

ROCK2-IN-7 (2-5 μM, 24h) inhibits ROCK2/pSTAT3 Signaling in HaCaT cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ROCK2-IN-7 (20-80 mg/kg, Oral gavage (p.o.), for seven consecutive days) reduces key interleukins associated with the IL-23/Th17 axis and important factors involved in keratinocyte proliferation in IMQ-induced skin inflammation model ^[1].
ROCK2-IN-7 (20-80 mg/kg, Oral gavage (p.o.), for seven consecutive days) inhibits the thickening of the epidermis and suppresses systemic immunity activation and attenuate inflammation in imiquimod (IMQ)-induced skin inflammation model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

445.53

C₂₆H₂₈FN₅O

3000541-95-4

O=C1N(C=C(C(C)=C1)F)C2=CC(CN[C@H]3CCC[C@@H](C3)NC4=CC=C5NN=CC5=C4)=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huang, Yun, et al. "Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment." Journal of Medicinal Chemistry (2023)  [Content Brief]